Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

February 1, 2014

Study Completion Date

February 1, 2014

Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
DRUG

eltrombopag

thrombopoietin receptor agonist

DRUG

Placebo

placebo for comparison

Trial Locations (33)

10021

GSK Investigational Site, New York

15224

GSK Investigational Site, Pittsburgh

19104

GSK Investigational Site, Philadelphia

27710

GSK Investigational Site, Durham

28009

GSK Investigational Site, Madrid

28046

GSK Investigational Site, Madrid

28203

GSK Investigational Site, Charlotte

32207

GSK Investigational Site, Jacksonville

32806

GSK Investigational Site, Orlando

32827

GSK Investigational Site, Orlando

33076

GSK Investigational Site, Bordeaux

38105

GSK Investigational Site, Memphis

45229

GSK Investigational Site, Cincinnati

48903

GSK Investigational Site, Barakaldo (Vizcaya)

61614

GSK Investigational Site, Peoria

75571

GSK Investigational Site, Paris

75935

GSK Investigational Site, Paris

77030

GSK Investigational Site, Houston

85016

GSK Investigational Site, Phoenix

87106

GSK Investigational Site, Albuquerque

92868

GSK Investigational Site, Orange

98105

GSK Investigational Site, Seattle

60611-2605

GSK Investigational Site, Chicago

02115

GSK Investigational Site, Boston

M5G 1X8

GSK Investigational Site, Toronto

H3T 1C5

GSK Investigational Site, Montreal

3015 GJ

GSK Investigational Site, Rotterdam

08035

GSK Investigational Site, Barcelona

CF14 4XW

GSK Investigational Site, Cardiff

W2 1NY

GSK Investigational Site, London

M13 9WL

GSK Investigational Site, Manchester

NE1 4LP

GSK Investigational Site, Newcastle upon Tyne

SO16 6YD

GSK Investigational Site, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY